A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
NCT00788931
Completed
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: Novartis Investigative Site, Mobile, Alabama +6 locations
Conditions: HER-2 Positive Breast Cancer, Metastatic Breast Cancer
Register for Updates
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
NCT01240655
Completed
This is a dose escalation study that will assess the safety and efficacy of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/16/2020
Locations: Dana Farber Cancer Institute SC, Boston, Massachusetts +6 locations
Conditions: Solid Tumors
Register for Updates
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
NCT02436668
Completed
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2020
Locations: Oncology Specialties, PC; Clearview Cancer Institute, Huntsville, Alabama +85 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
NCT02051751
Completed
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel combination
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2020
Locations: Highlands Oncology Group, Fayetteville, Arkansas +4 locations
Conditions: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Register for Updates
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
NCT01268059
Terminated
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2020
Locations: Research Site, Fountain Valley, California +28 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
NCT00269828
Terminated
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/23/2020
Locations: Desert Oasis Cancer Center, Casa Grande, Arizona +142 locations
Conditions: NSCLC
Register for Updates
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
NCT02280252
Completed
The need to understand LABC is especially compelling in populations and countries with limited resources, where breast cancer incidence is relatively low, but mortality is comparably high. In these settings access to appropriate cancer care is characteristically limited or often plainly nonexistent. In contrast to economically developed nations, where on average fewer than 20% of women present with breast cancer at advanced stages, LABC and metastatic disease are the most common stages at presen... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2020
Locations: NYU Langone Medical Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Northeast Arkansas Clinical Ch /ID# 128071, Jonesboro, Arkansas +224 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
NCT02625623
Completed
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2020
Locations: Rocky Mountain Cancer Centers 1800 Williams Street, Suite 100, Denver, Colorado +74 locations
Conditions: Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Register for Updates
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01412229
Completed
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2020
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +2 locations
Conditions: Head and Neck Cancer
Register for Updates
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
NCT02392507
Completed
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2020
Locations: Florida Hospital Cancer Institute, Orlando, Florida
Conditions: Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00026104
Completed
Randomized phase II trial to compare the effectiveness of gemcitabine, paclitaxel, and radiation therapy with or without tipifarnib in treating patients who have locally advanced pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining chemotherapy an... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/29/2020
Locations: Radiation Therapy Oncology Group, Philadelphia, Pennsylvania
Conditions: Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Register for Updates